o MediSpectra Inc., of Lexington, Mass., named James Myrtle vice president, clinical affairs.

o Micrologix Biotech Inc., of Vancouver, British Columbia, appointed to its board of directors John Avery, retired senior executive of Johnson & Johnson.

o MitoKor, of San Diego, appointed Craig Johnson vice president of finance and administration; Gonul Vellicelebi, vice president of research; and Andrew Granston, director of intellectual property.

o The Novartis Research Foundation, of Basel, Switzerland, named Peter Schultz head of the Novartis Institute for Functional Genomics, effective Jan. 1, 1999.

o Pharming, of Leiden, the Netherlands, named Thomas Stineman vice president of product development at Pharming Healthcare Inc., in the United States. Pharming Group NV, of the Netherlands, appointed Edna Venneker clinical development manager and Frank Neimoller group controller.

o Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., named to its board of directors Kurt Briner, recently retired president and CEO of Sanofi Pharma SA.

o ProScript Inc., of Cambridge, Mass., promoted Peter Elliott to vice president of pharmacology and drug development.

o Quidel Corp., of San Diego, named Robert Buchs vice president of sales and distribution management.

o Quigen NV, of Venio, the Netherlands, appointed Michael Burgett vice president of North American operations.

o ReSound Corp., of Redwood City, Calif., named Laureen DeBuono chief operating officer and chief financial officer.

o SkyePharma plc, of London, named Amy Ikerd president of Brightstone Pharma Inc.

o Sonus Pharmaceuticals Inc., of Bothell, Wash., named Gordon Brandt vice president, medical and clinical affairs.

o Syren Pharmaceuticals Ltd., of Cirencester, U.K., appointed to its board of directors Glyn Tonge, head of pharmaceuticals and health care within corporate finance for ING Barings.

o TheraCom, of Bethesda, Md., elected to its board of directors Robert Ingram, chairman, CEO and president of Glaxo Wellcome plc.

o Titan Pharmaceuticals Inc., of South San Francisco, named to its board of directors Eurelio Cavalier, former group vice president for the U.S. pharmaceutical business of Eli Lilly and Co.

o Tularik Inc., of South San Francisco, named to its scientific advisory board Nobel Prize winner Elias Corey.

o U.S. Labs, of Irvine, Calif., named Rick Ferguson vice president of business development.

o Vion Pharmaceuticals Inc., of New Haven, Conn., named to its board of directors Alan Kessman, former chairman, president and CEO of Executone Information Systems Inc.

o Yoshitomi Pharmaceutical Industries Ltd., of Osaka, Japan, named Ralph Galustian president and CEO of Alpha Therapeutic Corp., of Los Angeles, its U.S.-based plasma fractionation company.